Welcome!

News Feed Item

Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

LONDON, February 28, 2014 /PRNewswire/ --

Treating thrombosis - new analysis showing trends, R&D, and revenue forecasts

See the future of antithrombotic medicines. For those treatments you can get new sales predictions, also exploring research and development. Discover business potentials. And you assess results, trends, technologies, therapies, and opportunities.

Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your influence.

Read on, then, to explore those drug sales and find what they could be worth in future.

Forecasts to 2024 and other analyses predict and explain the antithrombotics market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with recent results, growth rates, market shares, and discussions.

Also you find the potential of research and development. The study also gives 82 tables, 70 charts, and interviews with four authorities in that field.

There you assess the future for treatments to prevent blood clotting or to dissolve blood clots. The following sections explain what the new investigation gives.

Forecasting of that world market and its segments - what's likely to happen?

What're the secrets of that industry's progress? Discover in our report overall world revenue to 2024 for antithrombotic medicines.

Also find individual revenue predictions to 2024 for eight therapeutic submarkets at world level:
• Antiplatelet agents
• Anticoagulants
• Fibrinolytic treatments.

And get forecasts for these anticoagulant drug classes:
• Heparins
• Direct thrombin inhibitors
• Direct factor Xa inhibitors
• Vitamin K antagonists
• Other therapeutics.

There you assess outlooks for sales expansion, hearing where you could profit. So investigate competition and rising sales. And see the lucrative possibilities there.

And you also find top products' potentials.

To see an exec summary of this report please email Sara Peerun on [email protected]

Predictions of leading products' sales

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 15 brands. Assess products including these:
• Plavix
• Lovenox
• Pradaxa
• Xarelto
• Activase
• Effient.

There you find drugs and years with highest predicted sales. Also you examine competitors. You see what's happening, understanding challenges, trends, competition and opportunities.

That work also shows geographical revenue predictions.

National markets - what outlooks for revenues?

In developed and developing countries, many opportunities for producers and sellers of those medicines will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and needs.

Events affecting developers, producers, and sellers

The report also explains issues, forces, and events affecting the antithrombotics industry and market from 2014, including these:
• Opportunities for novel therapies, including biological drugs (biologics) and warfarin replacements
• Pulmonary embolism, stroke prevention and acute coronary syndrome (ACS) - needs for thrombotic disease management
• Generic competition and development of existing drugs
• Guidelines for approval of biosimilar low molecular weight heparins (LMWHs)
• Demand for antidotes to novel oral anticoagulants
• Vitamin K antagonist and direct factor Xa inhibitor R&D pipelines.

You find, then, what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of companies and potential for market growth - what revenues are possible?

What happens next? From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from that applied haematology. Our study predicts that world market will reach $20.4bn in 2018.

You also see what organisations hold most potential. Examine companies, including these:
• Sanofi
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Bayer
• Johnson & Johnson.

And also these firms:
• The Medicines Company
• Genentech
• Otsuka
• Eli Lilly
• Sandoz.

You find 100 organisations mentioned. You also get four interviews with other authorities in that field, helping you stay ahead.

Ways Antithrombotic Drugs: World Industry and Market Prospects 2014-2024  helps

In particular, our new investigation gives you this knowledge:
• Revenues there to 2024 at world level, for 8 submarkets, and 15 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.

So with our data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your planning, decisions, authority, and competing.

Our new report is for everyone analysing medications for thrombosis treatment and prevention. There you discover trends, discussions and sales predictions. Avoid missing out - please order now.

To see an exec summary of this report please email Sara Peerun on [email protected]

Companies Listed in this report:
Abbott Laboratories
Ablynx
Aché
AdvanceCor
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
App Pharmaceuticals
ARCA Biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Barr Laboratories
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Canyon Pharmaceuticals
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica Group
Diakron Pharmaceuticals
Dr. Reddy's Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hoechst Marion Roussell
Hospira
Hypermarcas
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
Lee's Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Sandoz
Sanofi
Sun Pharmaceuticals
Takeda
Taro
Teva Pharmaceuticals
The Medicines Company
ThromboGenics
Tianjin Medical
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
USL Pharma
Virginia Commonwealth University
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila

To request an exec summary of this report please email Sara Peerun [email protected] or call Tel: +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1208/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2014-2024

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...